GeneNews' 2009 Revenues Dip on Lower Milestones

The firm said that its cash on hand is only sufficient to support its activities into the fourth quarter of this year. It expects its flagship ColonSentry test to be launched in the US this year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories